vs
Side-by-side financial comparison of Opera Ltd (OPRA) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Opera Ltd is the larger business by last-quarter revenue ($142.7M vs $103.7M, roughly 1.4× Twist Bioscience Corp). Opera Ltd runs the higher net margin — 12.8% vs -29.4%, a 42.2% gap on every dollar of revenue.
Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
OPRA vs TWST — Head-to-Head
Income Statement — Q1 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $142.7M | $103.7M |
| Net Profit | $18.3M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 14.8% | -31.7% |
| Net Margin | 12.8% | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q1 25 | $142.7M | — | ||
| Q2 24 | $211.6M | — |
| Q4 25 | — | $-30.5M | ||
| Q1 25 | $18.3M | — | ||
| Q2 24 | $34.1M | — |
| Q4 25 | — | 52.0% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -31.7% | ||
| Q1 25 | 14.8% | — | ||
| Q2 24 | 19.6% | — |
| Q4 25 | — | -29.4% | ||
| Q1 25 | 12.8% | — | ||
| Q2 24 | 16.1% | — |
| Q4 25 | — | $-0.50 | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $456.1M |
| Total Assets | — | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $456.1M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $638.1M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | $-34.8M | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPRA
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
